TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04610658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)
Study: NCT02049944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
Study: NCT01761266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg twice daily (BID) oral dosing.
Study: NCT01746771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM781-36B(Poziotinib)
Description: QD\*2weeks/3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg
Study: NCT01284114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Study: NCT01836679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT00598975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-102 100 mg/m2
Description: NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-102 125 mg/m2
Description: NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
Study: NCT04271098

Intervention type: PROCEDURE
Intervention: Open-Heart Surgery for nine months duration
Description: In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.

Intervention type: OTHER
Intervention: Relation between possible risk factors and hyperbilirubinemia
Description: Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.

Intervention type: OTHER
Intervention: Follow-up period
Description: All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
Study: NCT03897738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amberen
Description: Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smart B
Description: Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to Amberen and Smart B capsules.
Study: NCT01602341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2% QD
Description: AN2728 Topical Ointment, 2% QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 0.5% QD
Description: AN2728 Topical Ointment, 0.5% QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2% BID
Description: AN2728 Topical Ointment, 2% BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 0.5% BID
Description: AN2728 Topical Ointment, 0.5% BID
Study: NCT02399306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f.
Study: NCT01916980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
Study: NCT02546986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
Study: NCT04340622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supra-luminous LED
Description: 810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Light-emitting diode covered with aluminium foil
Study: NCT02844387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride solution
Description: Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
Study: NCT03786432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spira-C Interbody Device
Description: 40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
Study: NCT00600015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Sorafenib
Description: Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib + Placebo
Description: Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
Study: NCT01837693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: immediate colposcopy
Description: A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
Study: NCT02343484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelified ethanol combined to pulsed radiofrequency
Description: Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelified ethanol
Description: Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
Study: NCT00310830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
Study: NCT01354028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
Study: NCT00522925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 500mg capsule, once daily for 28 days
Study: NCT04494568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: HIFU Treatment of rectal endometriosis
Study: NCT03206723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage contact lens
Description: Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eyedrop
Description: Fluoroquinolone eyedrops 4x/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eyedrop
Description: Fluoroquinolone eyedrops 4x/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Hydrocone 1-2 tabs 4x/day if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Hydrocone 1-2 tabs 4x/day if needed
Study: NCT03334084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: intravenous or subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: intravenous or subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: intravenous or subcutaneous administration
Study: NCT02007551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Intervention
Description: The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
Study: NCT01350856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate 2
Description: Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate 4
Description: Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
Study: NCT01009957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 0.75 mg x 2 / day
Study: NCT03007212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization versus the standard treatment with sorafinib
Description: TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
Study: NCT03020862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice
Description: Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice
Description: Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
Study: NCT05576571

Intervention type: DIAGNOSTIC_TEST
Intervention: Met-score
Description: methylation analysis
Study: NCT02659592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of ovarian tissue
Description: operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
Study: NCT01827891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning (RIPC)
Description: Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
Study: NCT01243905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family psychoeducational therapy plus TAU
Description: Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual administered by physicians
Study: NCT02244710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor vs Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor vs Clopidogrel
Study: NCT04109495

Intervention type: OTHER
Group type: OTHER
Intervention: Smart phone application(NOOM)
Description: The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Non-user
Description: The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
Study: NCT00741156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Description: Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute